Every investor in Contineum Therapeutics, Inc. (NASDAQ:CTNM) should be aware of the most powerful shareholder groups. And the group that holds the biggest piece of the pie are institutions with 40 ...

Shares of CTNM stock opened at $6.67 on Thursday. The firm has a market capitalization of $171.94 million and a P/E ratio of -1.36. The firm’s fifty day moving average price is $9.39 and its two ...

Shares of Contineum Therapeutics stock opened at $6.77 on Friday. The firm has a 50-day simple moving average of $10.12 and a two-hundred day simple moving average of $14.38. The company has a ...

Fintel reports that on March 13, 2025, Jones Trading initiated coverage of Contineum Therapeutics (NasdaqGS:CTNM) with a Buy recommendation. As of March 4, 2025, the average one-year price target ...

Contineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for NI&I indications with significant unmet need. Contineum is ...

Baird lowered the firm’s price target on Contineum (CTNM) to $16 from $32 and keeps an Outperform rating on the shares. The firm said its Phase 2 results in relapsing-remitting MS is on track ...

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment ...

“2025 is shaping up to be a pivotal year, as we have several important clinical data readouts and trial initiations on the horizon,” said Carmine Stengone, CEO, Contineum (CTNM) Therapeutics.

Every investor in Contineum Therapeutics, Inc. (NASDAQ:CTNM) should be aware of the most powerful shareholder groups. And the group that holds the biggest piece of the pie are institutions with 40% ...